Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil

References

• American Cancer SocietyCancer facts & figures 20172017 Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdfAccessed June 30, 2017
   Google Scholar
• SEERCancer of the colon and rectum – cancer stat facts2017 Available from: https://seer.cancer.gov/statfacts/html/colorect.htmlAccessed June 30, 2017
   Google Scholar
• de GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol200018162938294710944126
   PubMed Web of Science ®Google Scholar
• CremoliniCLoupakisFAntoniottiCFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyLancet Oncol201516131306131526338525
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• CheesemanSLJoelSPChesterJDA ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancerBr J Cancer200287439339912177775
   PubMed Web of Science ®Google Scholar
• TournigandCAndreTAchilleEFOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol200422222923714657227
   PubMed Web of Science ®Google Scholar
• LoupakisFCremoliniCMasiGInitial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerN Engl J Med2014371171609161825337750
   PubMed Web of Science ®Google Scholar
• HochsterHSHartLLRamanathanRKSafety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE StudyJ Clin Oncol200826213523352918640933
   PubMed Web of Science ®Google Scholar
• Van CutsemEKohneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• Van CutsemELenzHJKohneCHFluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancerJ Clin Oncol201533769270025605843
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• TaberneroJYoshinoTCohnALRamucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyLancet Oncol201516549950825877855
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJFinal results from PRIME: random-ized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerAnn Oncol20142571346135524718886
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol200826335326533418854571
   PubMed Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch-repair deficiency predicts response of solid tumors to PD-1 blockadeScience2017357634940941328596308
   PubMed Web of Science ®Google Scholar
• FDAFDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication2017 Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm560040.htmAccessed July 12, 2017
   Google Scholar
• MarcusLLemerySJKhasarSFDA approval summary: TAS-102Clin Cancer Res201723122924292728213365
   PubMed Web of Science ®Google Scholar
• HeidelbergerCParsonsDGRemyDCSyntheses of 5-trifluoromethy-luracil and 5-trifluoromethyl-2′-deoxyuridineJ Med Chem196471514186018
   PubMed Web of Science ®Google Scholar
• HeidelbergerCBooharJKampschroerBFluorinated pyrimidines. XXIV. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2′-deoxyuridine-2-C-14Cancer Res19652537738114281103
   PubMed Web of Science ®Google Scholar
• ReyesPHeidelbergerCFluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotidesMol Pharmacol19651114304220791
   PubMed Web of Science ®Google Scholar
• SantiDVSakaiTTThymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′-deoxyuridylic acidBiochemistry19711019359836075146573
   PubMed Web of Science ®Google Scholar
• EcksteinJWFosterPGFiner-MooreJWatayaYSantiDVMechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2′-deoxyuridine 5′-monophosphateBiochemistry1994335015086150947999767
   PubMed Web of Science ®Google Scholar
• AherneGWHardcastleARaynaudFJackmanALImmunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cellsBiochem Pharmacol19965110129313018787544
   PubMed Web of Science ®Google Scholar
• WebleySDWelshSJJackmanALAherneGWThe ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibitionBr J Cancer200185344645211487279
   PubMed Web of Science ®Google Scholar
• EmuraTNakagawaFFujiokaAOhshimoHKitazatoKThymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse modelOncol Rep200411238138714719072
   PubMed Web of Science ®Google Scholar
• MarkleyJCChirakulPSologubDSigurdssonSTIncorporation of 2′-deoxy-5-(trifluoromethyl)uridine and 5-cyano-2′-deoxyuridine into DNABioorg Med Chem Lett200111182453245511549445
   PubMed Web of Science ®Google Scholar
• HeidelbergerCDexterDLWolbergWHClinical pharmacology of 5-trifluoromethyl-2′-deoxyuridine (F3TDR)Proc Am Assoc Cancer Res19701135
   Google Scholar
• FukushimaMSuzukiNEmuraTStructure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosidesBiochem Pharmacol200059101227123610736423
   PubMed Web of Science ®Google Scholar
• MoghaddamABicknellRExpression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activityBiochemistry1992314812141121461457409
   PubMed Web of Science ®Google Scholar
• BrownNSBicknellRThymidine phosphorylase, 2-deoxy-D-ribose and angiogenesisBiochem J1998334Pt 1189693094
   PubMed Web of Science ®Google Scholar
• van TriestBPinedoHMBlaauwgeersJLPrognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancerClin Cancer Res2000631063107210741735
   PubMed Web of Science ®Google Scholar
• TemminkOHEmuraTde BruinMFukushimaMPetersGJTherapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignanciesCancer Sci200798677978917441963
   PubMed Web of Science ®Google Scholar
• SuzukiNNakagawaFNukatsukaMFukushimaMTrifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaksExp Ther Med20112339339722977515
   PubMed Web of Science ®Google Scholar
• SuzukiNEmuraTFukushimaMMode of action of trifluorothymidine (TFT) against DNA replication and repair enzymesInt J Oncol201139126327021491084
   PubMed Web of Science ®Google Scholar
• HongDSAbbruzzeseJLBogaardKPhase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumorsCancer200610761383139016902987
   PubMed Web of Science ®Google Scholar
• OvermanMJVaradhacharyGKopetzSPhase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumorsInvest New Drugs200826544545418528634
   PubMed Web of Science ®Google Scholar
• DoiTOhtsuAYoshinoTPhase I study of TAS-102 treatment in Japanese patients with advanced solid tumoursBr J Cancer2012107342943422735906
   PubMed Web of Science ®Google Scholar
• OvermanMJKopetzSVaradhacharyGPhase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsCancer Invest200826879479918798063
   PubMed Web of Science ®Google Scholar
• BendellJCRosenLSMayerRJPhase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerCancer Chemother Pharmacol201576592593226370544
   PubMed Web of Science ®Google Scholar
• YoshinoTMizunumaNYamazakiKTAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialLancet Oncol20121310993100122951287
   PubMed Web of Science ®Google Scholar
• MayerRJVan CutsemEFalconeARandomized trial of TAS-102 for refractory metastatic colorectal cancerN Engl J Med2015372201909191925970050
   PubMed Web of Science ®Google Scholar
• WilhelmSMDumasJAdnaneLRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer2011129124525521170960
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• MasuishiTTaniguchiHHamauchiSRegorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparisonClin Colorectal Cancer2017162e15e2227670892
   PubMed Web of Science ®Google Scholar
• SuedaTSakaiDKudoTEfficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapiesAnticancer Res20163684299430627466548
   PubMed Web of Science ®Google Scholar
• HamauchiSYamazakiKMasuishiTNeutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102Clin Colorectal Cancer2017161515727522626
   PubMed Web of Science ®Google Scholar
• KasiPMKotaniDCecchiniMChemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyBMC Cancer20161646727412464
   PubMed Web of Science ®Google Scholar
• NishinaTYoshinoTShinozakiEOnset of neutropenia as an indicator of treatment response in the randomized phase II study of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (study J003-10040030)J Clin Oncol201634Suppl Abstr 3557
   Google Scholar
• OhtsuAYoshinoTFalconeAOnset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancerJ Clin Oncol201735Suppl 4S Abstr 775
   Google Scholar
• Van CutsemEOhtsuALegerCEffect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102)J Clin Oncol201735Suppl 4S Abstr 720
   Google Scholar
• Van CutsemEBenedettiFMMizuguchiHTAS-102 versus placebo (PBO) in patients (pts) ≥ 65 years (y) with metastatic colorectal cancer (mCRC): an age-based analysis of the recourse trialJ Clin Oncol201634Suppl 4S Abstr 638
   Google Scholar
• HustedtNDurocherDThe control of DNA repair by the cell cycleNat Cell Biol20161911928008184
   PubMed Web of Science ®Google Scholar
• SuenagaMSchirripaMCaoSGenetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancerAnn Oncol20172851015102228453695
   PubMed Web of Science ®Google Scholar
• ShintaniMUranoMTakakuwaYKurodaMKamoshidaSImmunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancerOncol Rep20102351345135020372850
   PubMed Web of Science ®Google Scholar
• TemminkOHBijnsdorpIVPrinsHJTrifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2Mol Cancer Ther2010941047105720371715
   PubMed Web of Science ®Google Scholar
• YoshinoTShinozakiEYamazakiKEffect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: results from two randomized studies of TAS-102 versus a placeboJ Clin Oncol201735Suppl 4S Abstr 529
   Google Scholar
• ZhangWSuenagaMSchirripaMGenetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancerJ Clin Oncol201634Suppl Abstr 3580
   Google Scholar
• TsukiharaHNakagawaFSakamotoKEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenograftsOncol Rep20153352135214225812794
   PubMed Web of Science ®Google Scholar
• BabaYTamuraTSatohYPanitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridineMol Oncol20171181065107728486761
   PubMed Web of Science ®Google Scholar
• KubokiYNishinaTShinozakiEAn investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)J Clin Oncol201533Suppl Abstr 3544
   Google Scholar
• SalemMEWangHFakihMAn open-label, multi-center, phase 2 study of switch maintenance with TAS-102 plus bevacizumab following oxaliplatin or irinotecan-based fluoropyrimidine-containing induction chemotherapy in patients with metastatic colorectal cancer: ALEXANDRIA studyJ Clin Oncol201634Suppl Abstr TPS3624
   Google Scholar
• KatoTKagawaYKomatsuYA phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): phase I resultsJ Clin Oncol201735Suppl 4S Abstr 770
   Google Scholar
• NukatsukaMNakagawaFTakechiTEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenograftsAnticancer Res20153594605461526254349
   PubMed Web of Science ®Google Scholar
• DoiTYoshinoTFuseNPhase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancerInvest New Drugs20153351068107726163340
   PubMed Web of Science ®Google Scholar
• MrossKBuchertMFrostAVascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisBMC Cancer20141451025012508
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• Van CutsemEYoshinoTHockeJOum’HamedZStudenyMTaberneroJRationale and design for the LUME-colon 1 study: a randomized, double-blind, placebo-controlled phase III trial of nintedanib plus best supportive care versus placebo plus best supportive care in patients with advanced colorectal cancer refractory to standard treatmentClin Colorectal Cancer2016151919426603056
   PubMed Web of Science ®Google Scholar
• NishinaTKubokiYShinozakiSA multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410); phase I resultsAnn Oncol201627Suppl 6 Abstr 472P
   Google Scholar